ChemoTech has been notified that the company's previously approved patent application regarding the unique functions that relate to the TSE technology has now also been approved in Japan. The patent refers to D-EECT, which was the development name for the technological platform that is the basis for ChemoTech's tumor-specific electroporation technology (TSE), which has been shown in clinical publications to have both efficacy and safety as well as potential in the treatment of various forms of cancer. The technology has been documented to be able to create an effective treatment, which also produces immunological effects, with only 5?10% of the previous maximum doses of cytostatics.

Today, TSE has been successfully used for the treatment of head and neck, breast, skin, and pancreatic cancer in humans as well as for several types of tumors in dogs and cats. In the past year, TSE has also been used with great success for the treatment of various tumors in horses, including sarcoids.